the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorChina National Biotec Group Company Limited
About this trial
This study evaluated the antibody persistence of Chinese children five years after they received four doses of sIPV, two doses of MMR vaccine and one dose of HepA-L vaccine.
Eligibility criteria
Qualifiers
Participants in the NCT04638985 or NCT04636827, and who have completed the vaccination of designated batch numbers of sIPV, MMR or HepA-L vaccines;
The time window from the day of enrollment to the date when the participants received the fourth dose of sIPV vaccine, the second dose of MMR vaccine, or the first dose of HepA-L vaccine was 60 to 66 months.
The informed consent form shall be signed by the participant or his/her legal guardian and dated.
Disqualifiers
None.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
600 Participants
are grouped into 1 trial groupSponsors and collaborators
China National Biotec Group Company Limited
Lead sponsor
Shaanxi Provincial Center for Disease Control and Prevention
Collaborator
Hubei Provincial Center for Disease Control and Prevention
Collaborator
Jiangsu Province Centers for Disease Control and Prevention
Collaborator
Anhui Provincial Center for Disease Control and Prevention
Collaborator
Sichuan Provincial Center for Disease Control and Prevention
Collaborator
Source ClinicalTrials.gov